hypercholesterolemia

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.

Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia.

Tafolecimab (IBI-306) is a humanised monoclonal antibody targeting PCSK9, capable of improving multiple lipid parameters (LDL, LDL-C, LDL-CFB, etc.), suitable for studying hypercholesterolaemia and mixed hyperlipidaemia.

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia. Frovocimab is used to study hypercholesterolemia.

Lerodalcibep (LIB003) is a potent, high-affinity inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is a recombinant fusion protein comprising a small PCSK9-binding protein fused to human serum albumin (HSA) to significantly extend its circulatory half-life. Lerodalcibep binds to circulating PCSK9 and blocks its interaction with low-density lipoprotein receptors (LDLR) on the hepatocyte surface, preventing lysosomal degradation of the receptors. This mechanism increases the density of LDLR on the liver surface, leading to the highly efficient clearance of LDL-cholesterol (LDL-C) from the blood.

Ongericimab (JS002) is a recombinant humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking the binding of PCSK9 to the low-density lipoprotein receptor (LDLR), the antibody reduces LDLR degradation, thereby increasing hepatic LDL-C uptake and lowering plasma cholesterol levels. It is primarily used to research hypercholesterolemia and cardiovascular risk management.

Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders.

Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).

Lodelcizumab (LGT 209) is a monoclonal antibody targeting the preprotein convertase Bacillus subtilis protease Kexin-9 (PCSK9) and is used to study hypercholesterolemia.

Anti-PCSK9 Antibody is a humanized monoclonal antibody targeting Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). PCSK9 is a serine protease primarily secreted by the liver that binds to the Low-Density Lipoprotein Receptor (LDLR) on the hepatocyte surface, promoting its internalization and lysosomal degradation, thereby preventing LDLR recycling to the cell surface. This reduces the liver's ability to clear LDL-cholesterol (LDL-C) from the blood. Anti-PCSK9 Antibody specifically binds to PCSK9, blocking its interaction with LDLR and inhibiting PCSK9-mediated LDLR degradation. This action increases the density of LDLR on hepatocytes, enhances LDL-C clearance, and significantly lowers serum cholesterol levels. It is widely used in research on hypercholesterolemia and atherosclerotic cardiovascular diseases.

ALD306 is a human monoclonal antibody (mAb) targeting PCSK9. It is utilized in research related to hypercholesterolemia.

Ticalicibart is a humanized IgG4κ monoclonal antibody inhibitor that targets PCSK9. It exhibits antihyperlipidemic activity and is applicable in the research of cardiovascular diseases such as hypercholesterolemia.